Skip to main content

Chikungunya Virus Infection

10
Pipeline Programs
5
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
6
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
7100%
+ 9 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Valneva
ValnevaAustria - Vienna
10 programs
1
5
Biological Vaccine VLA1553Phase 3Vaccine1 trial
VLA1553Phase 31 trial
VLA1553Phase 31 trial
VLA1553Phase 31 trial
VLA1553Phase 31 trial
+5 more programs
Active Trials
NCT07254702Enrolling By Invitation5,000Est. Feb 2027
NCT07163845Active Not Recruiting5,354Est. Dec 2026
NCT07414524Not Yet Recruiting200Est. Dec 2027
+7 more trials
Nordic Pharma
Nordic PharmaFrance - Paris
2 programs
1
1
CHIKV VLP vaccine boosterPhase 3Vaccine
CHIKV VLP/unadjuvantedPhase 2
Emergent BioSolutions
1 program
1
CHIKV VLP/unadjuvantedPhase 2
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
VRC-CHKVLP059-00-VPPhase 21 trial
Active Trials
NCT02562482Completed400Est. Mar 2018
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
2 programs
CHIKV VLP/unadjuvantedPHASE_21 trial
CHIKV VLP vaccine boosterPHASE_3Vaccine1 trial
Active Trials
NCT03483961Completed445Est. Sep 2020
NCT06007183Active Not Recruiting800Est. Aug 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ValnevaVLA1553
ValnevaVLA1553
Bavarian NordicCHIKV VLP vaccine booster
ValnevaVLA1553
ValnevaBiological Vaccine VLA1553
ValnevaVLA1553
ValnevaVLA1553 full dose
Bavarian NordicCHIKV VLP/unadjuvanted
Allergy TherapeuticsVRC-CHKVLP059-00-VP
ValnevaLive-attenuated CHIKV vaccine VLA1553
ValnevaLive-attenuated CHIKV vaccine VLA1553
ValnevaLive-attenuated CHIKV vaccine VLA1553
ValnevaLive-attenuated CHIKV vaccine VLA1553

Clinical Trials (13)

Total enrollment: 18,603 patients across 13 trials

NCT07133178ValnevaVLA1553

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

Start: Feb 2026Est. completion: Nov 20270
Phase 3Withdrawn
NCT06028841ValnevaVLA1553

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Start: Apr 2024Est. completion: Aug 20240
Phase 3Withdrawn
NCT06007183Bavarian NordicCHIKV VLP vaccine booster

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Start: Aug 2023Est. completion: Aug 2028800 patients
Phase 3Active Not Recruiting
NCT04838444ValnevaVLA1553

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Start: Apr 2021Est. completion: May 2031363 patients
Phase 3Active Not Recruiting
NCT04786444ValnevaBiological Vaccine VLA1553

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Start: Feb 2021Est. completion: Jan 2022409 patients
Phase 3Completed
NCT04546724ValnevaVLA1553

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Start: Sep 2020Est. completion: Oct 20214,128 patients
Phase 3Completed
NCT06106581ValnevaVLA1553 full dose

A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

Start: Dec 2023Est. completion: Jul 2025304 patients
Phase 2Completed
NCT03483961Bavarian NordicCHIKV VLP/unadjuvanted

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Start: Apr 2018Est. completion: Sep 2020445 patients
Phase 2Completed
NCT02562482Allergy TherapeuticsVRC-CHKVLP059-00-VP

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Start: Nov 2015Est. completion: Mar 2018400 patients
Phase 2Completed
NCT07414524ValnevaLive-attenuated CHIKV vaccine VLA1553

VLA1553-403 Pregnancy Surveillance Study

Start: Mar 2026Est. completion: Dec 2027200 patients
N/ANot Yet Recruiting
NCT07254702ValnevaLive-attenuated CHIKV vaccine VLA1553

Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Start: Feb 2026Est. completion: Feb 20275,000 patients
N/AEnrolling By Invitation
NCT07347002ValnevaLive-attenuated CHIKV vaccine VLA1553

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Start: Feb 2026Est. completion: Dec 20271,200 patients
N/AEnrolling By Invitation
NCT07163845ValnevaLive-attenuated CHIKV vaccine VLA1553

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Start: Sep 2025Est. completion: Dec 20265,354 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.